Ignite Creation Date:
2024-05-05 @ 11:46 PM
Last Modification Date:
2024-10-26 @ 10:39 AM
Study NCT ID:
NCT01417442
Status:
UNKNOWN
Last Update Posted:
2011-08-16
First Post:
2011-07-06
Brief Title:
BRAF V600E Mutations In Papillary Thyroid Carcinoma
Sponsor:
Bezmialem Vakif University
Organization:
Bezmialem Vakif University
Study Overview
Official Title:
Association Of Prognosis And BRAF V600E Mutations In Papillary Thyroid Carcinoma
Status:
UNKNOWN
Status Verified Date:
2011-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether BRAF V600E mutation in our patients with papillary thyroid cancer has an association with poor prognosis
Detailed Description:
Papillary thyroid carcinoma PTC is the most common type of thyroid malignancy and BRAF V600E mutation is the most common genetic alteration identified in PTC ranging from 25 to 80 with the average rate about 45 Various studies demonstrated a relationship between BRAF V600E mutation and aggressive characteristics of the cancer including the worse patient prognosis Butthere are no studies from Turkey regarding this topic So the investigators will examine BRAF V600E mutation in our patients with PTC and try to assess the role of this mutation in prognosis and further management of the patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None